SPOTLIGHT -
Newer Targeted Agents in NSCLC: TAK-788, an EGFR and HER2 Inhibitor
Robert Doebele discusses TAK-788, a first-in-class inhibitor of both EGFR and HER2 shown in an early-phase study to be active in NSCLC.
